Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus TERFONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus TERFONYL.
SULTEN-10 vs TERFONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
TERFONYL is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
2 g intravenously every 12 hours over 24 hours for susceptible infections.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Terminal elimination half-life is 2.5-4 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl < 30 mL/min).
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Renal excretion accounts for 70-90% of elimination as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal excretion constitutes 10-30%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic